Therapeutic | Bavituximab |
Target | Phosphatidylserine |
Heavy Chain | EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS |
Light Chain | DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2006 |
INN Year Recommended | 2007 |
Companies Involved | Avid Bioservices, IMV, Massachusetts General Hospital, Merck Sharp & Dohme, Peregrine Pharmaceuticals, University of Arizona, University of Texas Southwestern Medical Center, University of Texas M. D. Anderson Cancer Center |
Conditions Approved | na |
Conditions Active | Non-small cell lung cancer, Glioblastoma, Liver cancer, Solid tumours |
Conditions Discontinued | Breast cancer, Malignant melanoma, Pancreatic cancer, Brain cancer, Hepatitis C, HIV infections, Rectal cancer, Viral haemorrhagic fevers, Influenza virus infections, Prostate cancer |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]